Regeneron: Driven by Science

For over 25 years, Regeneron's vision has been to build an innovative company that consistently brings new medicines to patients with serious diseases.

Recent News

Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine


TARRYTOWN, N.Y. and PARIS, Oct. 1, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies evaluating investigational Dupixent® (dupilumab) in adult patients wit...

Read more

Upcoming Events

IR Thematic Call on Dupilumab: EADV 2016

10/01/16 at 7:00 AM ET

View Event

Form content here please :)